CVKD: Acquires 12-LOX Inhibitor for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

About this update from Cadrenal Therapeutics, Inc.

[{"type":"text","content":"By David Bautz, PhD","length":19,"tagName":"p"},{"type":"text","content":"NASDAQ:CVKD","length":11,"tagName":"p"},{"type":"text","content":"READ THE FULL CVKD RESEARCH REPORT","length":34,"tagName":"p"},{"type":"text","content":"Business Update","length":15,"tagName":"p"},{"type":"text","content":"Acquires 12-LOX Inhibitor VLX-1005 for the Treatment of HIT","length":59,"tagName":"p"},{"type":"text","content":"In December 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics. VLX-1005 is a first-in-class, highly selective small molecule inhibitor of 12-LOX for the treatment of heparin-induced thrombocytopenia (HIT). Two Phase 1 clinical trials in healthy volunteers have shown safety and tolerability across dosing, with no deaths or serious adverse events. A Phase 2 study in suspected HIT patients reported encouraging reductions in thromboembolic events, which is a clinically meaningful endpoint for regulators and clinicians. VLX-1005 holds Orphan Drug Designation and Fast Track status in the U.S. and Orphan Drug Designation in the E.U. This acquisition both strengthens Cadrenal’s pipeline with a late-stage asset and provides an opportunity to address another underserved therapeutic opportunity in the $40 billion global anticoagulation market.","length":950,"tagName":"p"},{"type":"text","content":"Background on HIT","length":17,"tagName":"p"},{"type":"text","content":"HIT is a severe, immune-mediated prothrombotic disorder triggered by exposure to heparin, an anticoagulant used widely in clinical practice (e.g., surgery, dialysis). It is estimated to occur in approximately 1 in 1500 hospital admissions (Dhakal et al., 2018). Data shows that certain variables can increase the risk of developing HIT, including cardiac surgery (Pishko et al., 2017) and exposure to unfractionated heparin vs. low molecular weight heparin (Warkentin et al., 1995), while a shorter exposure to heparin appears to decrease the risk of developing HIT (Smythe et al., 2007).","length":588,"tagName":"p"},{"type":"text","content":"Diagnosis of HIT uses the “4Ts Score”, which is a pre-test scoring system that assesses the probability of HIT (Lo et al., 2006). It is calculated as a sum of points from four components: Thrombocytopenia, Timing of platelet count fall...

More updates from Cadrenal Therapeutics, Inc.